Björling E - Search Results

1

Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage.

Mörner A, Björndal A, Albert J, Kewalramani VN, Littman DR, Inoue R, Thorstensson R, Fenyö EM, Björling E. Mörner A, et al. Among authors: bjorling e. J Virol. 1999 Mar;73(3):2343-9. doi: 10.1128/JVI.73.3.2343-2349.1999. J Virol. 1999. PMID: 9971817 Free PMC article.

2

CCR5 or CXCR4 is required for efficient infection of peripheral blood mononuclear cells by promiscuous human immunodeficiency virus type 2 primary isolates.

Mörner A, Björndal A, Leandersson AC, Albert J, Björling E, Jansson M. Mörner A, et al. Among authors: bjorling e. AIDS Res Hum Retroviruses. 2002 Feb 10;18(3):193-200. doi: 10.1089/08892220252781248. AIDS Res Hum Retroviruses. 2002. PMID: 11839153

3

Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection.

Björling E, Scarlatti G, von Gegerfelt A, Albert J, Biberfeld G, Chiodi F, Norrby E, Fenyö EM. Björling E, et al. Virology. 1993 Mar;193(1):528-30. doi: 10.1006/viro.1993.1160. Virology. 1993. PMID: 8438591

4

Human neutralizing human immunodeficiency virus type 2-specific Fab molecules generated by phage display.

Björling E, von Garrelts E, Mörner A, Ehnlund M, Persson MAA. Björling E, et al. J Gen Virol. 1999 Aug;80 ( Pt 8):1987-1993. doi: 10.1099/0022-1317-80-8-1987. J Gen Virol. 1999. PMID: 10466795

5

Fine characterization of a V3-region neutralizing epitope in human immunodeficiency virus type 2.

Mörner A, Achour A, Norin M, Thorstensson R, Björling E. Mörner A, et al. Among authors: bjorling e. Virus Res. 1999 Jan;59(1):49-60. doi: 10.1016/s0168-1702(98)00133-6. Virus Res. 1999. PMID: 10854165

6

Characterization of neutralizing sites in the second variable and fourth variable region in gp125 and a conserved region in gp36 of human immunodeficiency virus type 2.

Skott P, Achour A, Norin M, Thorstensson R, Björling E. Skott P, et al. Among authors: bjorling e. Viral Immunol. 1999;12(1):79-88. doi: 10.1089/vim.1999.12.79. Viral Immunol. 1999. PMID: 10333245

7

Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity.

Björling E, Broliden K, Bernardi D, Utter G, Thorstensson R, Chiodi F, Norrby E. Björling E, et al. Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6082-6. doi: 10.1073/pnas.88.14.6082. Proc Natl Acad Sci U S A. 1991. PMID: 2068087 Free PMC article.

8

Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection.

Lizeng Q, Skott P, Sourial S, Nilsson C, Andersson S S, Ehnlund M, Taveira N, Björling E. Lizeng Q, et al. Among authors: bjorling e. Virology. 2003 Apr 10;308(2):225-32. doi: 10.1016/s0042-6822(02)00088-0. Virology. 2003. PMID: 12706073 Free article.

9

Long-standing protection of macaques against cell-free HIV-2 with a HIV-2 iscom vaccine.

Putkonen P, Björling E, Akerblom L, Thorstensson R, Lövgren K, Benthin L, Chiodi F, Morein B, Biberfeld G, Norrby E, et al. Putkonen P, et al. Among authors: bjorling e. J Acquir Immune Defic Syndr (1988). 1994 Jun;7(6):551-9. J Acquir Immune Defic Syndr (1988). 1994. PMID: 8176640

10

Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2-exposed IgG-seronegative individuals.

Lizeng Q, Nilsson C, Sourial S, Andersson S, Larsen O, Aaby P, Ehnlund M, Björling E. Lizeng Q, et al. Among authors: bjorling e. J Virol. 2004 Jul;78(13):7016-22. doi: 10.1128/JVI.78.13.7016-7022.2004. J Virol. 2004. PMID: 15194778 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

56 results

Search Page

Filters